Home » Newsletters » BioWorld Science

BioWorld Science

Jan. 11, 2012

View Archived Issues

Phase II trial investigates effects of axitinib in metastatic melanoma

BioCryst reports on extension phase of BCX-4208 trial

Bristol-Myers Squibb announces planned acquisition

First-in-human data disclosed on ALT-801

Pearl Therapeutics completes phase IIb trials of COPD combination therapy

Otuska launches ophthalmic suspension in Japan

Amicus Therapeutics presents results from phase II study in Fabry's disease

BKM-120 assessed as monotherapy and in combination regimens in metastatic breast cancer

Novel antibacterial agents patented by U.S. universities

Roche prepares new series of phosphodiesterase 10A inhibitors

Abbott Laboratories and Enanta Pharmaceuticals present new HCV NS3 inhibitors

Novel anti-inflammatory agents discovered in U.K.

Afraxis presents new serine/threonine-protein kinase PAK inhibitors

Almirall presents novel phosphodiesterase 4 inhibitors

KalVista Pharmaceuticals and JDRF enter partnership

Endo Pharmaceuticals and BioDelivery Sciences sign agreement for pain therapy

Durect reports topline data on Posidur

Ensemble Therapeutics identifies unique small-molecule IL-17 antagonists

Adherex continues enrollment in phase II eniluracil regimen study

Shigamabs study reaches full enrollment

UCB reports encouraging topline data on Vimpat

Presidio Pharmaceuticals provides update on hepatitis C programs

Idenix Pharmaceuticals reports interim data from IDX-184 study

Leo Pharma in-licenses Virobay product

Rigel Pharmaceuticals advances two lead products to clinic

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 8, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 8, 2025.
Mesothelin is biomarker, potential target in arthritic bone damage
BioWorld Science
In a recent study published in Cell Reports Medicine, researchers from the Institute of Chinese Materia Medica of the China Academy of Chinese Medical Sciences...
Epigenetic technology could eliminate misfolded prion proteins
BioWorld Science
The number of deaths caused by prion diseases reaches about 30,000 annually. Only 5 months pass from the diagnosis of seemingly healthy patients to the fatal...
CTAD 2025: Diagnosing semaglutide’s failure in Alzheimer’s trials
BioWorld
A little over a week after announcing that the Evoke and Evoke+ studies failed to show that oral semaglutide could slow cognition decline in patients with...